DW4902: A New Oral GnRH Antagonist for Fibroid Bleeding

Uterine leiomyomas represent a major cause of abnormal uterine bleeding among premenopausal women. Consequently, clinicians continually seek effective medical options that avoid invasive surgical procedures. A novel oral GnRH antagonist known as DW4902 offers a targeted therapeutic approach. Furthermore, recent phase II data highlight its clinical efficacy in reducing excessive blood loss.
Clinical Impact of an Oral GnRH Antagonist
Uterine fibroids affect up to seventy percent of women during their reproductive years. In India, symptomatic fibroids cause substantial morbidity, frequent hospital visits, and severe iron-deficiency anemia. Heavy menstrual bleeding markedly impairs daily life and emotional well-being. Therefore, rapid non-surgical control of menorrhagia remains a critical therapeutic goal.
Traditional injectable GnRH agonists provide suppression but trigger an initial hormonal flare. In contrast, an oral GnRH antagonist induces immediate pituitary suppression without temporary hormone surges. DW4902 represents a promising addition to this modern drug class.
Study Design and Phase II Trial Outcomes
Investigators conducted a multicenter, randomized, double-blind, placebo-controlled trial across twelve tertiary hospitals in Korea. The study evaluated premenopausal women with fibroid-related heavy menstrual bleeding. Notably, all enrolled participants demonstrated a screening pictorial blood assessment chart score of at least 120. Researchers randomized 71 participants to receive placebo or once-daily DW4902 at 160 mg, 240 mg, or 320 mg.
Additionally, the trial monitored treatment response over twelve continuous weeks. The primary endpoint measured the proportion of patients achieving clinically meaningful bleeding reduction. Consequently, all DW4902 dosage groups demonstrated statistically significant improvements compared to placebo. Moreover, the oral therapy exhibited rapid onset and favorable tolerability. Adverse event rates remained consistent with predictable hypoestrogenic profiles.
Implications for Gynecological Practice
Oral antagonists offer distinct practical advantages over long-acting injectable agents. Specifically, daily oral administration allows rapid dose titration and immediate drug discontinuation if adverse effects occur. Furthermore, patient adherence improves when clinicians avoid painful intramuscular injections. For Indian clinicians managing chronic menorrhagia, oral therapies provide valuable flexibility prior to surgery or as bridging management. However, larger phase III trials must confirm long-term bone mineral safety and durability, areas further explored in advanced womens health training programs.
Frequently Asked Questions
Q1: What is DW4902 and how does it work?
DW4902 is an investigational oral GnRH receptor antagonist. It rapidly blocks pituitary GnRH receptors, which lowers circulating estrogen levels and suppresses fibroid-induced bleeding without causing an initial hormonal flare.
Q2: How does DW4902 differ from injectable GnRH agonists?
Injectable agonists initially trigger a temporary hormone flare before suppressing ovarian function. In contrast, DW4902 delivers rapid hormonal suppression immediately upon oral administration and offers faster reversibility after therapy ceases.
Q3: What doses did researchers evaluate in the Phase II trial?
Investigators tested once-daily oral doses of 160 mg, 240 mg, and 320 mg against placebo in premenopausal women with heavy menstrual bleeding.
References
- Song JY et al. Efficacy and Safety of the Oral Gonadotropin-Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial. BJOG. 2026 Nov 18. doi: 10.1111/1471-0528.70385. PMID: 43052059.
- Goitia Ibarra M, Díez Lázaro S, Azkuenaga Fernández A, Urquijo Beamonte E, Andrés Arribalzaga M, Martínez Zilloniz N, Cearsolo Michelena A. Once-daily oral gonadotropin-releasing hormone (GnRH) antagonists in the treatment of uterine fibroids: from evidence to clinical practice. Eur J Obstet Gynecol Reprod Biol. 2026. doi: 10.1016/j.ejogrb.2026.115365.
- Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. Nat Rev Dis Primers. 2016;2:16043.





